Abstract:Continuous loss of cardiomyocytes (CMs) is one of the fundamental characteristics of many heart diseases, which eventually can lead to heart failure. Due to the limited proliferation ability of human adult CMs, treatment efficacy has been limited in terms of fully repairing damaged hearts. It has been shown that cell lineage conversion can be achieved by using cell reprogramming approaches, including human induced pluripotent stem cells (hiPSCs), providing a promising therapeutic for regenerative heart medicine. Recent studies using advanced cellular reprogramming-based techniques have also contributed some new strategies for regenerative heart repair. In this review, hiPSC-derived cell therapeutic methods are introduced, and the clinical setting challenges (maturation, engraftment, immune response, scalability, and tumorigenicity), with potential solutions, are discussed. Inspired by the iPSC reprogramming, the approaches of direct cell lineage conversion are merging, such as induced cardiomyocyte-like cells (iCMs) and induced cardiac progenitor cells (iCPCs) derived from fibroblasts, without induction of pluripotency. The studies of cellular and molecular pathways also reveal that epigenetic resetting is the essential mechanism of reprogramming and lineage conversion. Therefore, CRISPR techniques that can be repurposed for genomic or epigenetic editing become attractive approaches for cellular reprogramming. In addition, viral and non-viral delivery strategies that are utilized to achieve CM reprogramming will be introduced, and the therapeutic effects of iCMs or iCPCs on myocardial infarction will be compared. After the improvement of reprogramming efficiency by developing new techniques, reprogrammed iCPCs or iCMs will provide an alternative to hiPSC-based approaches for regenerative heart therapies, heart disease modeling, and new drug screening.

Toward the latest advancements in cardiac regeneration using induced pluripotent stem cells (iPSCs) technology: approaches and challenges

Human Induced Pluripotent Stem Cell for Modeling Cardiovascular Diseases.

Human-Induced Pluripotent Stem Cell-Based Differentiation of Cardiomyocyte Subtypes for Drug Discovery and Cell Therapy

Current Status of Cardiac Regenerative Therapy Using Induced Pluripotent Stem Cells

Future prospects for regenerated heart using induced pluripotent stem cells

Non-viral reprogramming and induced pluripotent stem cells for cardiovascular therapy

Cardiac-derived stem cell-based therapy for heart failure: progress and clinical applications.

Current Status of Induced Pluripotent Stem Cells in Cardiac Tissue Regeneration and Engineering.

Advances in Cellular Reprogramming-Based Approaches for Heart Regenerative Repair

Human-Induced Pluripotent Stem Cell Technology and Cardiomyocyte Generation: Progress and Clinical Applications

Strategies and Challenges to Improve Cellular Programming-Based Approaches for Heart Regeneration Therapy

Applications of Induced Pluripotent Stem Cells (IPS) in the Study of Cardiovascular Disease

Advances in the Generation of Constructed Cardiac Tissue Derived from Induced Pluripotent Stem Cells for Disease Modeling and Therapeutic Discovery

Stem cell therapy for cardiac regeneration: past, present, and future

Induced pluripotent stem cells for cardiovascular therapeutics: Progress and perspectives

Human pluripotent stem cell models of cardiac disease: from mechanisms to therapies

Potential Applications Of Induced Pluripotent Stem Cells For Cardiovascular Diseases

The Application of Induced Pluripotent Stem Cells in Cardiac Disease Modeling and Drug Testing

Progress in preclinical research on induced pluripotent stem cell therapy for acute myocardial infarction

Recent advances in iPSC technologies involving cardiovascular and neurodegenerative disease modeling

Recent advances and future prospects in direct cardiac reprogramming